respiratori
tract
infect
rti
extrem
common
especi
first
year
life
everard
infect
due
one
mani
respiratori
virus
mainli
respiratori
syncyti
viru
rsv
griffith
et
al
influenza
viru
iv
antonova
et
al
rhinoviru
rv
principi
et
al
howev
parainfluenza
viru
piv
branch
falsey
adenoviru
adv
esposito
et
al
human
metapneumoviru
hmpv
principi
esposito
bocaviru
bv
principi
et
al
enteroviru
ev
hellfersce
et
al
also
play
relev
role
particularli
epidem
bacteria
caus
streptococcu
pyogen
common
caus
pharyng
paradis
streptococcu
pneumonia
typic
caus
lower
rti
esposito
principi
case
coinfect
two
virus
scotta
et
al
virus
bacteria
brealey
et
al
occur
mani
year
thought
knowledg
etiolog
respiratori
infect
essenti
facilit
appropri
manag
implement
effect
control
measur
presuppos
evid
show
given
viral
pathogen
caus
respiratori
infect
could
reduc
prescript
diagnost
test
use
antibiot
theoret
clinician
uncertainti
anxieti
patient
famili
member
could
also
reduc
gill
et
al
perspect
explain
laboratori
method
identifi
pathogen
respiratori
secret
develop
cours
mani
year
initi
cell
cultur
immunofluoresc
assay
rapid
antigen
direct
test
use
test
mainli
use
viru
identif
due
higher
frequenc
viral
rti
howev
none
test
consid
complet
satisfactori
clinic
use
although
cell
cultur
exhibit
high
specif
good
sensit
expens
long
turnaround
time
leland
ginocchio
gharabaghi
et
al
immunofluoresc
assay
achiev
moder
sensit
identifi
eight
virus
sometim
requir
long
turnaround
time
ginocchio
mcadam
final
rapid
antigen
direct
test
although
abl
provid
result
minut
high
specif
avail
rsv
iv
adenoviru
low
sensit
gharabaghi
et
al
ginocchio
mcadam
problem
overcom
least
part
recent
year
method
base
nucleic
acid
amplif
becam
avail
method
exhibit
enhanc
sensit
specif
detect
broad
rang
pathogen
within
accept
turnaround
time
singl
polymeras
chain
reaction
pcr
known
respiratori
virus
sever
multiplex
platform
use
pcr
method
nucleic
acid
amplif
simultan
detect
two
virus
develop
hanson
couturi
highcomplex
multiplex
panel
assay
simultan
detect
virus
mahoni
et
al
virus
two
three
atyp
bacteria
gonsalv
et
al
virus
four
bacteria
beckmann
hirsch
total
pathogen
includ
bacteria
fast
track
diagnost
within
hour
develop
howev
bacteria
play
relev
role
determin
respiratori
infect
systemat
includ
multiplex
platform
market
larg
evalu
clinic
practic
patient
admit
emerg
depart
hospit
ward
intens
care
unit
despit
evalu
actual
role
diagnost
measur
precis
defin
particular
yet
establish
whether
avail
laboratori
measur
abl
identifi
sever
potenti
etiolog
agent
respiratori
infect
offer
real
advantag
term
diagnost
accuraci
choic
appropri
therapi
reduct
social
econom
problem
strictli
associ
pediatr
respiratori
diseas
moreov
major
case
nt
allow
identif
antimicrobi
resist
commonli
use
drug
paper
deriv
present
avail
studi
regard
discuss
multiplex
platform
base
molecular
method
use
hospit
requir
specif
equip
laboratori
technician
consider
knowledg
train
experi
beckmann
hirsch
esposito
et
al
biomerieux
fast
track
diagnost
moreov
platform
turnaround
time
significantli
shorter
cultur
gener
much
longer
rapid
test
take
hour
give
reliabl
result
limit
emerg
depart
intens
care
unit
mani
patient
requir
immedi
diagnost
therapeut
decis
beckmann
hirsch
esposito
et
al
biomerieux
fast
track
diagnost
recent
develop
platform
respiratori
panel
accept
turnaround
time
h
much
longer
rapid
test
biofir
final
number
sampl
process
per
run
significantli
vari
assay
assay
case
case
alreadi
cite
assay
one
sampl
could
process
per
run
platform
higher
sampl
throughput
sampl
chan
et
al
problem
epidem
sever
patient
test
simultan
multiplex
assay
significantli
sensit
specif
compar
rapid
immunochromatograph
test
immunofluoresc
assay
howev
multiplex
assay
detect
viabl
nonviabl
virus
bacteria
lead
debat
result
beckmann
hirsch
esposito
et
al
biomerieux
fast
track
diagnost
gener
present
develop
market
multiplex
assay
exhibit
compar
perform
regard
sensit
specif
detect
coinfect
previou
comparison
luminex
nx
tag
rpp
assay
biofir
film
array
respiratori
panel
farp
biomerieux
beckmann
hirsch
luminex
rvp
fast
assay
esposito
et
al
term
abil
detect
common
pathogen
reveal
discord
lower
although
turnaround
time
workflow
simplic
risk
contamin
lower
luminex
nx
tag
rpp
chen
et
al
tang
et
al
systemat
review
metaanalysi
huang
et
al
studi
accuraci
farp
nanospher
verigen
rv
test
holog
luminex
genprob
prodess
assay
holog
detect
iv
iv
b
viru
rsv
hmpv
av
show
assay
high
diagnost
accuraci
area
receiv
oper
characterist
curv
auroc
equal
test
virus
except
adenoviru
auroc
final
similarli
high
accuraci
demonstr
anyplex
ii
advansur
rv
realq
rv
yun
et
al
allplex
respiratori
panel
allplex
seegen
republ
korea
recent
releas
onestep
realtim
revers
transcriptionpcr
method
simultan
detect
multipl
pathogen
demonstr
rapid
accur
method
detect
respiratori
virus
particularli
case
multipl
viral
infect
lee
lee
studi
compar
allplex
assay
prodesseproflu
profast
holog
madison
wi
usa
genexpert
flursv
xc
cepheid
usa
iv
rsv
detect
found
accuraci
sensit
respect
three
assay
show
specif
posit
predict
valu
ppv
neg
predict
valu
npv
allplex
prodess
genexpert
respect
gimferr
et
al
gener
accuraci
multiplex
platform
identifi
respiratori
pathogen
similar
singl
pcr
although
case
slightli
lower
effici
shown
exampl
luminex
nx
tag
rpp
compar
singl
pcr
shown
multiplex
assay
lower
sensit
cv
cv
oversensit
sever
virus
lead
sever
falseposit
result
worst
accuraci
found
hmpv
ppv
chen
et
al
similarli
compar
standard
pcr
assay
sensit
taqman
array
card
adv
respect
test
virus
assay
specif
coeffici
variat
viru
control
rang
weinberg
et
al
howev
previous
report
bacteri
pathogen
caus
respiratori
infect
systemat
includ
avail
multiplex
platform
relev
limit
clinic
practic
assay
lack
inform
regard
antimicrobi
resist
commonli
use
antiinfect
drug
evid
show
viru
present
respiratori
secret
patient
rti
necessarili
mean
particular
infecti
agent
caus
diseas
viru
etiolog
agent
virus
also
asymptomat
carri
shed
sever
week
infect
cure
therefor
virus
identifi
asymptomat
incub
period
without
actual
role
diseas
contrari
thought
year
ago
virus
asymptomat
colon
airway
children
admit
hospit
nonrespiratori
diseas
healthi
children
attend
day
care
shown
carrier
least
one
respiratori
viru
case
although
viral
load
gener
lower
carrier
symptomat
subject
jansen
et
al
moe
et
al
notabl
rate
asymptomat
colon
vari
significantli
viru
viru
detect
iv
rsv
hmpv
piv
gener
indic
diseas
frequenc
asymptomat
carriag
agent
rel
uncommon
contrast
detect
certain
virus
rais
mani
doubt
due
high
frequenc
virus
identifi
asymptomat
children
rhedin
et
al
despit
capac
caus
upper
lower
rti
trigger
asthma
chronic
obstruct
pulmonari
diseas
exacerb
esposito
et
al
parker
et
al
principi
et
al
rv
viru
frequent
found
asymptomat
patient
principi
et
al
studi
healthi
children
year
old
follow
weekli
nasopharyng
sampl
month
winter
season
total
nasopharyng
sampl
obtain
sampl
test
posit
rv
associ
respiratori
symptom
suggest
asymptomat
colon
carriag
common
also
bv
chow
esper
detect
respiratori
secret
healthi
children
frequenc
observ
patient
rti
von
linstow
et
al
similar
find
report
adv
detect
nasopharynx
healthi
children
case
colvin
et
al
rhedin
et
al
pathogen
asymptomat
carri
also
pathogen
commonli
detect
recent
multiplex
platform
carriag
mycoplasma
pneumonia
mp
identifi
mani
asymptomat
children
although
preval
vari
accord
site
studi
denmark
spuesen
et
al
usa
wood
et
al
period
respiratori
sampl
collect
spring
summer
colvin
et
al
similarli
certain
percentag
healthi
children
shown
test
posit
chlamydophila
pneumonia
cp
emr
et
al
block
et
al
falck
et
al
longterm
viral
shed
previou
infect
render
result
multiplex
platform
poorli
effect
identifi
etiolog
diseas
howev
signific
differ
longterm
shed
among
variou
infecti
agent
gener
agent
uncommonli
carri
agent
shed
day
opposit
trend
appli
agent
frequent
asymptomat
carri
although
certain
influenza
patient
shed
viru
day
shed
typic
peak
day
onset
symptom
ip
et
al
although
except
munywoki
et
al
rsv
shed
estim
last
day
hall
et
al
okiro
et
al
contrast
rv
bc
gener
shed
longer
time
studi
involv
children
age
month
bocaviru
infect
shown
case
viru
persist
respiratori
secret
day
despit
rapid
disappear
clinic
manifest
wagner
et
al
prolong
shed
report
rv
loeffelholz
et
al
although
differ
accord
type
infect
strain
daleno
et
al
longlast
persist
respiratori
secret
acut
infect
demonstr
adv
kalu
et
al
atyp
bacteria
persist
mp
dna
throat
common
median
carriag
time
week
diseas
onset
rang
month
nilsson
et
al
cp
detect
month
pathogen
temporarili
interrupt
replic
cycl
expos
antimicrobi
later
resum
replic
lead
gener
infecti
particl
panzetta
et
al
final
virus
detect
incub
period
without
play
role
determin
actual
diseas
incub
period
viral
respiratori
infect
gener
short
calcul
lessler
et
al
period
last
day
confid
interv
ci
adv
day
ci
human
coronaviru
day
ci
iv
day
ci
iv
b
day
ci
piv
day
ci
rsv
day
ci
rv
howev
period
virus
detect
respiratori
secret
lead
diagnost
mistak
defin
etiolog
diseas
complic
detect
coinfect
practic
imposs
establish
agent
true
caus
agent
unfortun
coinfect
common
studi
involv
children
radiograph
confirm
cap
viral
coinfect
demonstr
case
enrol
patient
viral
infect
similar
find
report
viralbacteri
coinfect
studi
nolan
et
al
find
surpris
previou
concurr
viral
rti
favor
develop
secondari
bacteri
coinfect
throughout
airway
augment
bacteri
adher
colon
dysregul
innat
adapt
immun
respons
immunosuppress
releas
bacteria
biofilm
alter
microbiom
mechan
virus
favor
bacteri
superinfect
bakaletz
conclus
multiplex
platform
despit
significantli
increas
possibl
detect
pathogen
present
respiratori
secret
child
respiratori
infect
offer
advantag
comparison
tradit
diagnost
test
regard
identif
true
etiolog
agent
diseas
multiplex
assay
use
benefit
determin
infecti
agent
potenti
respons
rti
strongli
limit
low
number
drug
activ
respiratori
target
current
avail
diagnost
platform
present
drug
influenza
viru
rsv
atyp
bacteria
licens
furthermor
debat
drug
use
subject
suffer
infect
due
sensit
agent
systemat
use
neuraminidas
inhibitor
european
center
diseas
prevent
control
baloxavir
marboxil
hayden
et
al
recommend
case
influenza
influenza
frequent
mild
diseas
advantag
drug
administr
limit
margin
reduct
diseas
durat
consequ
use
drug
reserv
extrem
sever
case
although
true
efficaci
case
definit
demonstr
lessler
et
al
european
center
diseas
prevent
control
rsv
infect
treat
ribavirin
licens
drug
treatment
viru
howev
ribavirin
difficult
use
costli
teratogen
weak
evid
efficaci
ribavirin
typic
use
sever
case
occur
immunocompromis
subject
brendish
clark
although
sever
new
drug
rsv
develop
like
next
year
licens
univers
use
present
treatment
rsv
infect
remain
base
support
measur
hydrat
administr
xing
proesman
antibiot
effect
vitro
atyp
bacteria
gener
recommend
larg
use
pathogen
suspect
demonstr
caus
rti
esposito
et
al
kohlhoff
hammerschlag
howev
actual
relev
drug
clinic
practic
debat
evid
seem
suggest
slightli
effect
effect
spuesen
et
al
gardin
et
al
children
macrolid
use
mp
cp
drug
effect
atyp
bacteria
prescrib
patient
particularli
youngest
administr
tetracyclin
chloramphenicol
lead
sever
advers
event
ketolid
streptogramin
limit
use
pediatr
fluoroquinolon
licens
use
subject
year
age
principi
esposito
howev
mani
studi
compar
clinic
cours
mp
cp
infect
children
treat
macrolid
drug
ineffect
pathogen
report
differ
two
group
suggest
macrolid
useless
principi
esposito
addit
macrolid
use
use
presum
effect
reduc
abus
antibiot
emerg
resist
strain
principi
esposito
final
despit
high
risk
nephrotox
cidofovir
drug
licens
treatment
cytomegaloviru
cmv
retin
hivinfect
patient
use
treat
adv
infect
immunocompromis
subject
ganapathi
et
al
retrospect
evalu
includ
children
show
case
viral
clearanc
clinic
respons
achiev
howev
four
patient
expir
despit
viral
clearanc
one
death
directli
ascrib
adv
infect
howev
cidofovir
licens
treatment
adv
drug
reserv
sever
case
occur
immunocompromis
children
consid
potenti
solut
treat
mildtomoder
case
respiratori
diseas
otherwis
healthi
children
ganapathi
et
al
recent
prospect
studi
includ
children
adult
rti
aim
determin
antibiot
misus
show
viral
infect
common
children
adult
antibiot
overus
occur
children
significantli
higher
level
adult
studi
highlight
need
effect
intervent
decreas
antibiot
overus
rti
patient
age
van
houten
et
al
propos
use
test
identifi
virus
reduc
use
antibiot
prescript
diagnost
measur
risk
hospit
acquisit
among
patient
length
stay
pediatr
clinic
set
advantag
test
medic
social
econom
point
view
therefor
enorm
howev
result
studi
multiplex
assay
conflict
test
use
pediatr
patient
admit
intens
care
unit
advantag
antibiot
prescript
demonstr
byington
et
al
contrast
retrospect
evalu
use
test
pediatr
inpati
show
posit
test
result
associ
decreas
length
stay
hospit
shorter
durat
antibiot
least
patient
common
respiratori
diagnos
schulert
et
al
howev
wishaupt
et
al
avail
result
within
h
lead
advantag
term
hospit
admiss
length
hospit
stay
durat
antibiot
use
antibiot
treatment
initi
recent
retrospect
studi
multiplex
assay
test
children
admit
emerg
depart
prior
admiss
within
first
day
hospit
reveal
patient
result
test
avail
less
like
receiv
antibiot
day
moreov
patient
like
isol
day
compar
control
subramoni
et
al
final
recent
studi
conduct
special
highrisk
set
hematolog
oncolog
unit
suggest
diagnos
asymptomat
viru
infect
rsv
influenza
use
lower
risk
hospit
acquisit
screen
program
prove
use
identifi
asymptomat
infect
patient
viral
shed
thu
reduc
risk
transmiss
potenti
nosocomi
cluster
rsv
influenza
viru
hematooncolog
ward
baier
et
al
hand
less
satisfactori
result
also
report
studi
evalu
impact
rapid
test
immunofluoresc
assay
although
market
prepar
shown
exhibit
sensit
specif
higher
vo
et
al
cochran
review
doan
et
al
analyz
four
studi
regard
impact
rapid
viral
diagnosi
children
admit
emerg
depart
report
advantag
rapid
diagnosi
lower
rate
chest
radiographi
rel
risk
rr
ci
effect
length
visit
blood
urin
test
demonstr
moreov
trend
toward
decreas
antibiot
use
demonstr
differ
test
untest
children
signific
knowledg
bronchiol
case
associ
detect
rsv
nasopharyng
secret
lead
advantag
children
posit
result
rapid
test
receiv
similar
blood
test
radiolog
examin
moreov
although
children
test
posit
sever
diseas
virolog
test
rsv
identifi
children
risk
global
rapid
test
rsv
consid
useless
attitud
explain
test
recommend
sever
expert
ralston
et
al
rapid
test
singl
viru
seem
posit
impact
physician
attitud
satisfactori
effect
antibiot
consumpt
clinic
cours
diseas
rapid
test
influenza
sever
year
ago
esposito
et
al
show
children
posit
rapid
influenza
test
significantli
less
like
neg
test
test
undergo
routin
blood
examin
vs
p
p
receiv
antibiot
vs
p
p
children
posit
test
also
tend
lower
incid
although
signific
chest
radiograph
vs
lower
likelihood
admiss
vs
similar
result
report
recent
cantai
et
al
show
diagnosi
influenza
follow
reduct
blood
punctur
reduct
chest
xray
reduct
lumbar
punctur
reduct
urin
cultur
reduct
antibiot
treatment
reduct
hospit
stay
altogeth
reduct
result
reduct
medic
cost
estim
per
season
final
studi
evalu
impact
multiplex
platform
expect
patient
parent
gener
laboratori
test
request
consid
effect
measur
improv
judgement
clinician
howev
diagnosi
viral
diseas
laboratori
test
interpret
simplif
complex
clinic
problem
bronchiol
due
rsv
sever
inclus
among
viral
diagnosi
may
lead
parent
dissatisfact
especi
given
specif
therapi
avail
rsv
support
measur
prescrib
cabral
et
al
moreov
definit
inform
avail
impact
multiplex
assay
clinician
anxieti
data
need
complet
evalu
impact
multiplex
assay
clinic
practic
multiplex
platform
identif
respiratori
virus
atyp
bacteria
allow
identif
infecti
agent
caus
respiratori
infect
infant
children
highli
like
platform
particularli
import
studi
specif
plan
evalu
epidemiolog
respiratori
pathogen
clinic
research
contrari
routin
use
pediatr
clinic
practic
remain
debat
use
commun
pediatr
respiratori
diseas
diagnos
moreov
allow
overcom
limit
tradit
diagnost
test
respiratori
pathogen
differenti
carriag
infect
seem
influenc
therapi
effect
drug
avail
iv
rsv
seem
significantli
impact
socioeconom
problem
strictli
relat
pediatr
respiratori
infect
seem
howev
justifi
presenc
sever
clinic
manifest
immunocompromis
patient
specif
treatment
option
avail
particularli
use
simultan
platform
allow
identif
antimicrobi
resist
commonli
use
drug
highli
like
platform
particularli
high
sensit
specif
low
turnaround
time
becom
essenti
new
drug
effect
safe
respiratori
virus
avail
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
